NCNadia M. Chu

Nadia M. Chu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nadia M. Chu has a total of 193 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Physical frailty, self-rated health, and all-cause mortality: implications for understanding resilience in aging

    by Vishaldeep Kaur Sekhon, Roshni Wani, Chenkai Wu, Nadia M Chu, Qian-Li Xue

    Background: Frailty and poor self-rated health (SRH) as potential indicators of reduced resilience are associated with all-cause mortality. However, it is lesser known whether these associations are independent of each other, physical disability or disease burden, and whether SRH remains predictive of mortality among frail older adults. Methods: We leveraged the National Health and Aging Trends Study of US Medicare beneficiaries, followed annually from 2011 to 2019. Baseline assessments included physical frailty and SRH (excellent/very good, good, or fair/poor). Cox models examined associations with all-cause mortality, adjusting for demographic characteristics and comorbidities. Sensitivity analyses excluded participants with probable or possible dementia at baseline. Results: Of the 7425 participants at baseline, 14% were physically frail, and 25% reported fair/poor SRH. Although frailty was positively correlated with fair/poor SRH, 12% of frail participants reported excellent/very good health, and 6.6% of those with fair/poor SRH were non-frail. Over a median follow-up of 4.3 years, 29% died. Compared to non-frail participants, pre-frailty and frailty were associated with 1.4- and 2.0-fold increased hazard of mortality, respectively, after adjusting for SRH (p < .001); reporting good and fair/poor SRH was associated with 29% and 59% higher hazard of mortality compared to excellent/very good SRH, respectively, after adjusting for frailty (p < .001). Fair/poor SRH was associated with higher mortality among the frail. Sensitivity analyses yielded similar results. Conclusion: Physical frailty and SRH, while related, capture distinct aspects of health. Each independently and jointly predicts mortality, with SRH retaining prognostic value in frail individuals. Incorporating both measures may improve risk stratification and guide tailored interventions.


  • Open Access

    Identifying Research Priorities for Cognition in CKD

    by Jamie Alexiuk, Oksana Harasemiw, Jessica Vanderlinden, Davide Verrelli, Brett Tarca, David Collister, Heitor Ribeiro, Bonnie Corradetti, Kevin Fowler, Fabio Manfredini, et al.

    Key Points: Cognitive impairment is prevalent in CKD, affecting quality of life, self-management, and decision-making. It worsens with disease progression. This Delphi study engaged diverse stakeholders to identify 27 critical research questions on cognitive impairment in CKD for future focus. Top priorities include preventing cognitive decline, preserving cognition, routine monitoring, and adjusting dialysis treatment to reduce cognitive impairment. Background: Cognition is a research priority for people living with CKD, but identification of critical research questions is lacking. This study aimed to determine which cognition-related research questions are most important to CKD stakeholders. Methods: A modified Delphi technique with three survey rounds was used. The study sample included three panels (People with lived CKD experience, Researchers, and Clinicians) recruited through international patient and kidney research networks, kidney societies, and snowball sampling with email invitations. Survey rounds were distributed electronically through Research Electronic Data Capture. In round 1 (October 2021–May 2022), respondents contributed three important research questions regarding cognition in CKD (free text). After deduplication and qualitative synthesis, respondents ranked the importance of these questions on a nine-point Likert scale in round 2 (February–April 2023). Questions with mean and median ratings of >7 by at least two respondent panels or rated critically important by the lived experience panel were reranked in round 3 (August–September 2023) and assessed for consensus to identify the final list of priority research questions. Results: Respondents (n=152) identified 125 and 44 discrete questions after rounds 1 and 2, respectively. The final shortlist included 27 questions in eight categories. The most critical research question identified was “What factors prevent cognitive impairment in people receiving dialysis?” Overall, respondents prioritized questions focusing on prevention and treatment of cognitive impairment. Scores between the panels were significantly different for 16 questions. Those with lived CKD experience prioritized quality of life, researchers emphasized developing interventions to mitigate cognitive impairment, and clinicians prioritized the effect of CKD treatment on cognitive impairment. Conclusions: Through an established consensus methodology involving key stakeholder groups, we identified 27 critical research questions about cognition in CKD. These questions should guide future study design and outcome selection.


  • Sleep Disorders and Dementia Risk in Older Patients with Kidney Failure

    by Jane J. Long, Yusi Chen, Byoungjun Kim, Sunjae Bae, Yiting Li, Babak J. Orandi, Nadia M. Chu, Aarti Mathur, Dorry L. Segev, Mara A. McAdams-DeMarco

    Key Points: Older patients with kidney failure who are newly diagnosed with sleep disorders are at higher risk of developing any type of dementia, vascular dementia, and other/mixed types of dementia. For older patients with kidney failure who are diagnosed with obstructive sleep apnea, positive airway pressure therapy is an intervention that is associated with lower dementia risk. Background: Community-dwelling older adults with sleep disorders are at higher risk of developing dementia. Greater than 50% of older patients with kidney failure experience sleep disorders, which may explain their high burden of dementia. Methods: Among 216,158 patients (aged 66 years and older) with kidney failure (United States Renal Data System; 2008–2019), we estimated the risk of dementia (including subtypes) associated with sleep disorders using Cox proportional hazards models with propensity score weighting. We tested whether positive airway pressure (PAP) therapy was associated with reduced dementia risk among patients with obstructive sleep apnea (OSA). Results: 26.3% of patients were diagnosed with sleep disorders; these patients had a higher 5-year unadjusted cumulative incidence for any type of dementia (36.2% versus 32.3%; P < 0.001), vascular dementia (4.4% versus 3.7%; P < 0.001), and other/mixed dementia (29.3% versus 25.8%; P < 0.001). Higher risk of any type of dementia was identified in patients with insomnia (adjusted hazard ratio [aHR], 1.42; 95% confidence interval [CI], 1.34 to 1.51), sleep-related breathing disorders (SRBDs) (aHR, 1.20, 95% CI, 1.17 to 1.23), and other sleep disorders (aHR, 1.24; 95% CI, 1.11 to 1.39). Higher vascular dementia risk was observed in patients with insomnia (aHR, 1.43; 95% CI, 1.19 to 1.73) and SRBDs (aHR, 1.15; 95% CI, 1.07 to 1.24). Patients with SRBDs (aHR, 1.07; 95% CI, 1.00 to 1.15) were at higher risk of Alzheimer disease. Among patients with OSA, PAP therapy was associated with lower risk of any type of dementia (aHR, 0.82; 95% CI, 0.76 to 0.90) and vascular dementia (aHR, 0.65; 95% CI, 0.50 to 0.85). Conclusions: Older patients with kidney failure and sleep disorders are at a higher risk of dementia. Sleep is an important modifiable factor that should be considered for targeted interventions to mitigate dementia risk in patients with kidney failure. For patients with OSA, PAP therapy is associated with lower dementia risk.


  • Sleep duration and cognitive function among older adults with chronic kidney disease: results from the National Health and Nutrition Examination Survey (2011–2014)

    by Fatima Warsame, Nadia M Chu, Jingyao Hong, Aarti Mathur, Deidra C Crews, George Bayliss, Dorry L Segev, Mara A McAdams-DeMarco

    Short and long sleep durations are associated with cognitive dysfunction. Given the increased prevalence of sleep abnormalities in the chronic kidney disease (CKD) population, we tested whether the association between sleep duration and cognitive function differed between older adults with and without CKD. This was a study of 3215 older adults (age ≥60 years) enrolled in the National Health and Nutrition Examination Survey (2011–14) evaluating sleep duration, cognitive function (immediate recall, delayed recall, verbal fluency, executive function and processing speed and global cognition) and kidney function. We quantified the association between sleep duration and cognitive function using linear regression and tested whether the associations differed among those with CKD and without using a Wald test for interaction. Among 3215 participants, 13.3% reported 2–5 hours of sleep/day, 75.2% reported 6–8 hours, and 11.5% reported ≥9 hours. Persons with CKD were more likely to sleep ≥9 hours [odds ratio 1.73 (95% confidence interval 1.22–2.46)]. Among participants with CKD, those with a sleep duration ≥9 hours demonstrated worse global cognitive function (P for interaction = .01), immediate recall (P for interaction = .01) and verbal fluency (P for interaction = .004) than those with a sleep duration of 6–8 h; no differences were observed for participants with CKD who slept 2–5 hours. Among participants without CKD, sleep was not associated with any measures of cognitive function. Longer sleep duration is associated with worse cognitive function only among persons with CKD, and global cognition, delayed recall and verbal fluency are particularly affected. Studies should identify interventions to improve sleep patterns and quality in this population.


  • Open Access

    Domains for a Comprehensive Geriatric Assessment of Older Adults with Chronic Kidney Disease: Results from the CRIC Study

    by Venus Chiu, Alden L. Gross, Nadia M. Chu, Dorry Segev, Rasheeda K. Hall, Mara McAdams-DeMarco, the CRIC Study Investigators

    Introduction: A comprehensive geriatric assessment (CGA) tailored to the chronic kidney disease (CKD) population would yield a more targeted approach to assessment and care. We aimed to identify domains of a CKD-specific CGA (CKD-CGA), characterize patterns of these domains, and evaluate their predictive utility on adverse health outcomes. Methods: We used data from 864 participants in the Chronic Renal Insufficiency Cohort aged ≥55 years and not on dialysis. Constituents of the CKD-CGA were selected a priori. Latent class analysis informed the selection of domains and identified classes of participants based on their domain patterns. The predictive utility of class membership on mortality, dialysis initiation, and hospitalization was examined. Model discrimination was assessed with C-statistics. Results: The CKD-CGA included 16 domains: cardiovascular disease, diabetes, five frailty phenotype components, depressive symptoms, cognition, five kidney disease quality-of-life components, health literacy, and medication use. A two-class latent class model fit the data best, with 34.7% and 65.3% in the high- and low-burden of geriatric conditions classes, respectively. Relative to the low-burden class, participants in the high-burden class were at increased risk of mortality (aHR = 2.09; 95% CI: 1.56, 2.78), dialysis initiation (aHR = 1.63; 95% CI: 1.06, 2.52), and hospitalization (aOR = 2.00; 95% CI: 1.38, 2.88). Model discrimination was the strongest for dialysis initiation (C-statistics = 0.86) and moderate for mortality and hospitalization (C-statistics = 0.70 and 0.66, respectively). Conclusion: With further validation in an external cohort, the CKD-CGA has the potential to be used in nephrology practices for assessing and managing geriatric conditions in older adults with CKD.


  • Open Access

    Delirium, changes in cognitive function, and risk of diagnosed dementia after kidney transplantation

    by Nadia M. Chu, Sunjae Bae, Xiaomeng Chen, Jessica Ruck, Alden L. Gross, Marilyn Albert, Karin J. Neufeld, Dorry L. Segev, Mara A. McAdams-DeMarco


  • Secondary hyperparathyroidism (CKD-MBD) treatment and the risk of dementia

    by Aarti Mathur, JiYoon B Ahn, Whitney Sutton, Nadia M Chu, Alden L Gross, Dorry L Segev, Mara McAdams-DeMarco

    Elevated parathyroid hormone (PTH) levels have been reported as a potential risk factor for cognitive impairment. Compared with the general population, older adults with end-stage renal disease (ESRD) who are frequently affected by secondary hyperparathyroidism (SHPT) are at increased risk of developing dementia. The main objective of our study was to evaluate if the risk of dementia in older (age ≥66 years) ESRD patients differed if they were treated for SHPT. Using the United States Renal Data System and Medicare claims, we identified 189 433 older adults without a diagnosis of dementia, who initiated dialysis between 2006 and 2016. SHPT treatment was defined as the use of vitamin D analogs, phosphate binders, calcimimetics or parathyroidectomy. We quantified the association between treated SHPT and incident dementia during dialysis using a multivariable Cox proportional hazards model with inverse probability weighting, considering SHPT treatment as a time-varying exposure. Of 189 433 older ESRD adults, 92% had a claims diagnosis code of SHPT and 123 388 (65%) were treated for SHPT. The rate of incident dementia was 6 cases per 100 person-years among SHPT treated patients compared with 11 cases per 100 person-years among untreated patients. Compared with untreated SHPT patients, the risk of dementia was 42% lower [adjusted hazard ratio (aHR) = 0.58, 95% confidence interval (CI): 0.56–0.59] among SHPT treated patients. The magnitude of the beneficial effect of SHPT treatment differed by sex (Pinteraction = .02) and race (Pinteraction ≤ .01), with females (aHR = 0.56, 95% CI: 0.54–0.58) and those of Asian (aHR = 0.51, 95% CI: 0.46–0.57) or Black race (aHR = 0.51, 95% CI: 0.48–0.53) having a greatest reduction in dementia risk. Receiving treatment for SHPT was associated with a lower risk of incident dementia among older patients with ESRD. This work provides additional support for the treatment of SHPT in older ESRD patients.


  • Long-Term Trajectories of Frailty and Its Components After Kidney Transplantation

    by Nadia M Chu, Jessica Ruck, Xiaomeng Chen, Qian-Li Xue, Silas P Norman, Dorry L Segev, Mara A McAdams-DeMarco

    Background: Frailty is common and associated with poor outcomes among kidney transplant (KT) recipients. While frailty improves in the first 3 months post-KT with restored kidney function, longer-term trajectories are likely to plateau/decline due to aging and other stressors (eg, immunosuppression). We evaluated longer-term post-KT trajectories of the physical frailty phenotype (PFP) and its components in adult patients at 2 centers. Methods: PFP components were measured at admission, 1, 3, 6 months, 1 year, and annually thereafter post-KT. We used adjusted mixed-effects models to describe repeated measures of continuous components (weight, gait speed, grip strength, activity) and generalized estimating equations to quantify longitudinal, binomial response patterns (PFP; exhaustion). Results: Among 1 336 recipients (mean age = 53) followed for a median of 1.9 years (interquartile range [IQR] = 0.1–3.2), likelihood of frailty declined in the first 2.5 years post-KT (adjusted odds ratio [aOR] = 0.96, 95% confidence interval [CI]: 0.95, 0.98), but increased after 2.5 years post-KT (aOR = 1.03, 95% CI: 1.00, 1.05). In the first 2.5 years post-KT, recipients demonstrated increases in weight (0.4 lbs/month, 95% CI: 0.3, 0.5), grip strength (0.2 kg/month, 95% CI: 0.1, 0.2), and activity (23.9 kcal/month, 95% CI: 17.5, 30.2); gait speed remained stable (−0.01 s/month, 95% CI: 0.01, 0.003). Additionally, likelihood of becoming exhausted declined post-KT (OR = 0.99, 95% CI: 0.98, 1.00). After 2.5 years post-KT, recipients demonstrated decreased grip strength (−0.07 kg/month, 95% CI: −0.12, −0.01) and activity (−20 kcal/month, 95% CI: −32.3, −8.2); they had stable weight (−0.003 lbs/month, 95% CI: −0.17, 0.16), gait speed (−0.003 s/month, 95% CI: −0.02, 0.01), and likelihood of becoming exhausted (OR = 1.01, 95% CI: 0.99, 1.02). Conclusion: Despite frailty improvements in the first 2.5 years, recipients’ frailty worsened after 2.5 years post-KT. Specifically, they experienced gains in strength, activity, and exhaustion in the first 2.5 years post-KT, but declined in strength and activity after 2.5 years post-KT while experiencing persistent slowness. Clinicians should consider monitoring recipients for worsening frailty after 2.5 years despite shorter-term improvements.


  • Chronic kidney disease, physical activity and cognitive function in older adults—results from the National Health and Nutrition Examination Survey (2011–2014)

    by Nadia M Chu, Jingyao Hong, Oksana Harasemiw, Xiaomeng Chen, Kevin J Fowler, Indranil Dasgupta, Clara Bohm, Dorry L Segev, Mara A McAdams-DeMarco, the Global Renal Exercise Network

    Cognitive impairment is common among persons with chronic kidney disease (CKD), due in part to reduced kidney function. Given that physical activity (PA) is known to mitigate cognitive decline, we examined whether associations between CKD stage and global/domain-specific cognitive function differ by PA. We leveraged 3223 participants (≥60 years of age) enrolled in National Health and Nutrition Examination Survey (NHANES, 2011–2014), with at least one measure of objective cognitive function [immediate recall (CERAD-WL), delayed recall (CERAD-DR), verbal fluency (AF), executive function/processing speed (DSST), global (average of four tests) or self-perceived memory decline (SCD)]. We quantified the association between CKD stage {no CKD: estimated glomerular filtration rate [eGFR] ≥60 mL/min/1.73 m2 and albuminuria [albumin:creatinine ratio (ACR)] 2 and ACR ≥30 mg/g or eGFR 30–59 mL/min/1.73 m2; stages G4 and G5: eGFR 2} and cognitive function using linear regression (objective measures) and logistic regression (SCD), accounting for sampling weights for nationally representative estimates. We tested whether associations differed by PA [Global Physical Activity Questionnaire, high PA ≥600 metabolic equivalent of task (MET) · min/week versus low PA interaction = 0.01). Specifically, among participants with low PA, those with CKD stages G4 and G5 had lower global cognitive function [difference = −0.57 SD (95% CI −0.82 to −0.31)] compared with those without CKD. Among those with high PA, no difference was found [difference = 0.10 SD (95% CI −0.29–0.49)]. Similarly, the CKD stage was only associated with immediate recall, verbal fluency, executive function and processing speed among those with low PA; no associations were observed for delayed recall or self-perceived memory decline. CKD is associated with lower objective cognitive function among those with low but not high PA. Clinicians should consider screening older patients with CKD who have low PA for cognitive impairment and encourage them to meet PA guidelines.


  • Cognitive impairment burden in older and younger adults across the kidney transplant care continuum

    by Nadia M. Chu, Xiaomeng Chen, Alden L. Gross, Michelle C. Carlson, Jacqueline M. Garonzik‐Wang, Silas P. Norman, Aarti Mathur, Maheen Z. Abidi, Daniel C. Brennan, Dorry L. Segev, et al.

    Background: Younger kidney transplant (KT) candidates and recipients may have cognitive impairment due to chronic diseases and reliance on dialysis.Methods: To quantify cognitive impairment burden by age across the KT care continuum, we leveraged a two‐center cohort study of 3854 KT candidates at evaluation, 1114 recipients at admission, and 405 recipients at 1‐year post‐KT with measured global cognitive performance (3MS) or executive function (Trail Making Test). We also estimated burden of severe cognitive impairment that affects functional dependence (activities of daily living [ADL] < 6 or instrumental activities of daily living [IADL] < 8).Results: Among KT candidates, global cognitive impairment (18–34 years: 11.1%; 35–49 years: 14.0%; 50–64 years: 19.5%; ≥65 years: 22.0%) and severe cognitive impairment burden (18–34 years: 1.1%; 35–49 years: 3.0%; 50–64 years: 6.2%; ≥65 years: 7.7%) increased linearly with age. Among KT recipients at admission, global cognitive impairment (18–34 years: 9.1%; 35–49 years: 6.1%; 50–64 years: 9.3%; ≥65 years: 15.7%) and severe cognitive impairment burden (18–34 years: 1.4%; 35–49 years: 1.4%; 50–64 years: 2.2%; ≥65 years: 4.6%) was lower. Despite lowest burden of cognitive impairment among KT recipients at 1‐year post‐KT across all ages (18–34 years: 1.7%; 35–49 years: 3.4%; 50–64 years: 4.3%; ≥65 years: 6.5%), many still exhibited severe cognitive impairment (18–34 years: .0%; 35–49 years: 1.9%; 50–64 years: 2.4%; ≥65 years: 3.5%).Conclusion: Findings were consistent for executive function impairment. While cognitive impairment increases with age, younger KT candidates have a high burden comparable to community‐dwelling older adults, with some potentially suffering from severe forms. Transplant centers should consider routinely screening patients during clinical care encounters regardless of age.